A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands

Expert Rev Anticancer Ther. 2015 Feb;15(2):157-64. doi: 10.1586/14737140.2015.974563. Epub 2014 Nov 29.

Abstract

Introduction: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.

Methods: We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.

Results: The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.

Discussion: Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.

Keywords: brainstem tumor; chemotherapy; clinical trial; diffuse intrinsic pontine glioma; high-grade glioma; pediatric oncology; radiotherapy; treatment.

MeSH terms

  • Brain Stem Neoplasms / diagnosis
  • Brain Stem Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Female
  • Glioma / diagnosis
  • Glioma / pathology
  • Glioma / therapy*
  • Humans
  • Male
  • Netherlands
  • Pons / pathology*
  • Prognosis
  • Retrospective Studies
  • Survival Rate